Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience

Background: Merkel cell carcinoma (MCC) is an aggressive malignancy of presumed neuroendocrine origin. Most case series of MCC are limited by low case numbers and are not specific to head and neck tumours. The purpose of this study was to provide a focused review of head and neck MCC diagnosis and m...

Full description

Bibliographic Details
Main Authors: C.M. Hurley, D. ALNafisee, D. Jones, J.L. Kelly, P.J. Regan, A.J. Hussey, N. McInerney
Format: Article
Language:English
Published: Elsevier 2022-09-01
Series:JPRAS Open
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2352587822000365
_version_ 1817981533407936512
author C.M. Hurley
D. ALNafisee
D. Jones
J.L. Kelly
P.J. Regan
A.J. Hussey
N. McInerney
author_facet C.M. Hurley
D. ALNafisee
D. Jones
J.L. Kelly
P.J. Regan
A.J. Hussey
N. McInerney
author_sort C.M. Hurley
collection DOAJ
description Background: Merkel cell carcinoma (MCC) is an aggressive malignancy of presumed neuroendocrine origin. Most case series of MCC are limited by low case numbers and are not specific to head and neck tumours. The purpose of this study was to provide a focused review of head and neck MCC diagnosis and management in a single Irish institution. Methods: Patient's demographics, tumour characteristics, pathological diagnosis, surgical treatment, adjuvant treatment, subsequent management and clinical course were collected. Estimates of progression-free MCC survival rates were calculated by the Kaplan–Meier statistical model. A Pearson product-moment correlation coefficient examined the association between surgical margins and disease-free follow-up. Results: In total, 11 patients were treated for head and neck MCC with a mean age of 79.6 years (range = 69–91 years). The mean average follow-up duration of patients was 18.3 months. Of the cohort, 18% (n=2) had a sentinel node biopsy (SLNB). A selective neck dissection was subsequently performed in 18% (n=2). In total, 72% (n=8) of patients received adjuvant radiotherapy. Median disease-specific survival was 15 months for the SLNB group and 17 months for the non-SLNB group, not statistically significant (p=0.23). There was no significant association between surgical margins and disease-free follow (p=0.65). Conclusions: Our case series adds to a limited body of evidence of head and neck MCC. Surgery remains the treatment priority in localized disease, with an increasing role of SLNB for accurate prognostication and staging. Early management of stage I disease results in moderate long-term disease-free survivability.
first_indexed 2024-04-13T23:08:24Z
format Article
id doaj.art-72422505bb8843b9966b22a20305d89f
institution Directory Open Access Journal
issn 2352-5878
language English
last_indexed 2024-04-13T23:08:24Z
publishDate 2022-09-01
publisher Elsevier
record_format Article
series JPRAS Open
spelling doaj.art-72422505bb8843b9966b22a20305d89f2022-12-22T02:25:38ZengElsevierJPRAS Open2352-58782022-09-0133161170Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional ExperienceC.M. Hurley0D. ALNafisee1D. Jones2J.L. Kelly3P.J. Regan4A.J. Hussey5N. McInerney6Department of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, Ireland; Correspondence: Mr Ciaran Hurley, MB BCh BAO MCh, MRCS, Specialist Registrar, Department of Plastic and Reconstructive Surgery, University Hospital Galway, Co. Galway, Republic of Ireland.Department of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandDepartment of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandDepartment of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandDepartment of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandDepartment of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandDepartment of Plastic & Reconstructive Surgery, University Hospital Galway, Galway, Ireland; Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin, IrelandBackground: Merkel cell carcinoma (MCC) is an aggressive malignancy of presumed neuroendocrine origin. Most case series of MCC are limited by low case numbers and are not specific to head and neck tumours. The purpose of this study was to provide a focused review of head and neck MCC diagnosis and management in a single Irish institution. Methods: Patient's demographics, tumour characteristics, pathological diagnosis, surgical treatment, adjuvant treatment, subsequent management and clinical course were collected. Estimates of progression-free MCC survival rates were calculated by the Kaplan–Meier statistical model. A Pearson product-moment correlation coefficient examined the association between surgical margins and disease-free follow-up. Results: In total, 11 patients were treated for head and neck MCC with a mean age of 79.6 years (range = 69–91 years). The mean average follow-up duration of patients was 18.3 months. Of the cohort, 18% (n=2) had a sentinel node biopsy (SLNB). A selective neck dissection was subsequently performed in 18% (n=2). In total, 72% (n=8) of patients received adjuvant radiotherapy. Median disease-specific survival was 15 months for the SLNB group and 17 months for the non-SLNB group, not statistically significant (p=0.23). There was no significant association between surgical margins and disease-free follow (p=0.65). Conclusions: Our case series adds to a limited body of evidence of head and neck MCC. Surgery remains the treatment priority in localized disease, with an increasing role of SLNB for accurate prognostication and staging. Early management of stage I disease results in moderate long-term disease-free survivability.http://www.sciencedirect.com/science/article/pii/S2352587822000365Merkel cellHead and neckNeuroendocrineSentinel nodeRadiotherapy
spellingShingle C.M. Hurley
D. ALNafisee
D. Jones
J.L. Kelly
P.J. Regan
A.J. Hussey
N. McInerney
Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
JPRAS Open
Merkel cell
Head and neck
Neuroendocrine
Sentinel node
Radiotherapy
title Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
title_full Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
title_fullStr Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
title_full_unstemmed Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
title_short Head and Neck Merkel Cell Carcinoma: A 12-Year Single Institutional Experience
title_sort head and neck merkel cell carcinoma a 12 year single institutional experience
topic Merkel cell
Head and neck
Neuroendocrine
Sentinel node
Radiotherapy
url http://www.sciencedirect.com/science/article/pii/S2352587822000365
work_keys_str_mv AT cmhurley headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT dalnafisee headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT djones headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT jlkelly headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT pjregan headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT ajhussey headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience
AT nmcinerney headandneckmerkelcellcarcinomaa12yearsingleinstitutionalexperience